Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Theseus Pharmaceuticals Inc (THRX)

Theseus Pharmaceuticals Inc (THRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 179,574
  • Shares Outstanding, K 44,230
  • Annual Sales, $ 0 K
  • Annual Income, $ -50,610 K
  • EBIT $ -67 M
  • EBITDA $ -67 M
  • 60-Month Beta 3.98
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.79
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.34
  • Most Recent Earnings $-0.31 on 11/17/23
  • Next Earnings Date 03/14/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/23
See More
  • Average Estimate -0.33
  • Number of Estimates 1
  • High Estimate -0.33
  • Low Estimate -0.33
  • Prior Year -0.35
  • Growth Rate Est. (year over year) +5.71%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.98 +2.01%
on 01/22/24
4.11 -1.22%
on 02/07/24
+0.03 (+0.74%)
since 01/12/24
3-Month
2.92 +39.04%
on 11/14/23
4.20 -3.33%
on 12/27/23
+1.92 (+89.72%)
since 11/13/23
52-Week
2.05 +98.05%
on 11/13/23
12.37 -67.18%
on 05/02/23
-7.19 (-63.91%)
since 02/13/23

Most Recent Stories

More News
Theseus Pharmaceuticals Announces Business Highlights and Reports Second Quarter 2023 Financial Results

IND submission for THE-349 in EGFR-mutant NSCLC expected in Q4 2023 Development candidate nomination for BCR-ABL program in CML and Ph+ ALL expected in H1 2024...

THRX : 4.06 (unch)
Why These 2 Biotech Stocks Made Big Moves Late Thursday

Markets kept powering higher on the day.

COMP : 6.01 (-3.53%)
$NASX : 19,641.04 (+0.35%)
$DOWI : 42,625.13 (-0.50%)
$SPX : 5,930.74 (unch)
ACAD : 16.86 (-0.06%)
THRX : 4.06 (unch)
Theseus Pharmaceuticals to Discontinue Enrollment in Phase 1/2 Study and Terminate Development of THE-630 in Patients with GIST

-- Decision follows two dose-limiting toxicities related to hand-foot skin reaction observed in Cohort 7 (27 mg) -- -- Company prioritizing THE-349, a...

THRX : 4.06 (unch)
Theseus Pharmaceuticals to Participate in the Jefferies Healthcare Conference

/PRNewswire/ -- Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) ("Theseus"), a clinical-stage biopharmaceutical company focused on improving the lives of cancer...

THRX : 4.06 (unch)
Theseus Pharmaceuticals Reports Initial Dose Escalation Data from Ongoing Phase 1/2 Trial of THE-630 in Patients with Advanced GIST

-- THE-630 demonstrates encouraging safety profile through Cohort 6 (18 mg), supportive of continued dose escalation -- -- Dose-dependent reductions observed...

THRX : 4.06 (unch)
Theseus Pharmaceuticals Announces Business Highlights and Reports First Quarter 2023 Financial Results

/PRNewswire/ -- Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) (Theseus or the Company), a clinical-stage biopharmaceutical company focused on improving the...

THRX : 4.06 (unch)
Theseus Pharmaceuticals Initial Dose Escalation Results from Ongoing Phase 1/2 Trial of THE-630 Accepted for Online Publication at 2023 ASCO Annual Meeting

/PRNewswire/ -- Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) (Theseus or the Company), a clinical-stage biopharmaceutical company focused on improving the...

THRX : 4.06 (unch)
Theseus Pharmaceuticals to Participate in Upcoming Investor Conferences

/PRNewswire/ -- Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) ("Theseus"), a clinical-stage biopharmaceutical company focused on improving the lives of cancer...

THRX : 4.06 (unch)
Theseus Pharmaceuticals to Participate in the Cantor Future of Oncology Virtual Symposium

/PRNewswire/ -- Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) ("Theseus"), a clinical-stage biopharmaceutical company focused on improving the lives of cancer...

THRX : 4.06 (unch)
Theseus Pharmaceuticals Announces Business Highlights and Reports Fourth Quarter and Full Year 2022 Financial Results

/PRNewswire/ -- Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) (Theseus or the Company), a clinical-stage biopharmaceutical company focused on improving the...

THRX : 4.06 (unch)

Business Summary

Theseus Pharmaceuticals Inc. is a biopharmaceutical company. It focused on improving the lives of cancer patients through the discovery, development and commercialization of transformative targeted therapies. The company's principal product candidate includes THE-630. Theseus Pharmaceuticals Inc. is...

See More

Key Turning Points

3rd Resistance Point 4.08
2nd Resistance Point 4.07
1st Resistance Point 4.07
Last Price 4.06
1st Support Level 4.06
2nd Support Level 4.05
3rd Support Level 4.05

See More

52-Week High 12.37
Fibonacci 61.8% 8.43
Fibonacci 50% 7.21
Fibonacci 38.2% 5.99
Last Price 4.06
52-Week Low 2.05

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar